Orion Corporation's financial reporting and Annual General Meeting in 2019
Orion Corporation will publish its Financial Statement Release 2018 on Wednesday, 6 February 2019.
The publication dates of the Interim Reports and the Half-Year Financial Report in 2019 are as follows:
| Interim Report January-March 2019 |
Half-Year Financial Report January-June 2019
Interim Report January-September 2019
| Thursday, 25 April 2019 |
Wednesday, 17 July 2019
Wednesday, 23 October 2019
The Financial Statements and the Report of the Board of Directors for 2018 will be published on the Company's website at the latest in week 10/2019.
The Annual General Meeting is planned to be held on Tuesday, 26 March 2019 in Helsinki.
Orion's financial reports and related presentation material are available on the Group's website at http://www.orion.fi/investors promptly after the publishing. The website also provides a possibility to register on Orion's mailing lists for releases.
| Timo Lappalainen |
President and CEO
| Olli Huotari |
SVP, Corporate Functions
Lilli Riikonen, Communications Manager
tel. +358 50 966 2319
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2017 amounted to EUR 1,034 million and the company had about 3,200 employees. Orion's A and B shares are listed on Nasdaq Helsinki.